Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RiboX Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001
Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.
Product Name : RXRG001
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing
Details : Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.
Product Name : AAV-AQP1
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing